Latest News & Features
Americas
Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate. 20 May 2021
Medtech
The Trademark Trial and Appeal Board (TTAB) will start expediting the review and issuance of ex parte appeal decisions related to COVID-19 trademarks. 20 May 2021
Big Pharma
Roche Group’s subsidiary Spark Therapeutics has filed a complaint against rival gene therapy company Bluebird Bio, accusing it of infringing its ‘Spark’ trademark. 20 May 2021
Plant Varieties
Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent. 18 May 2021
Biotechnology
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept). 18 May 2021
Big Pharma
The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines. 17 May 2021
Big Pharma
The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid. 13 May 2021
Big Pharma
Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents. 13 May 2021
Big Pharma
India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India. 13 May 2021
article
More and more medical uses of psychoactives are coming forward creating somewhat of a gold rush for psilocybin patents. As plants that are medicines can’t be patented, it is synthesised molecules and method of delivery patents which are highly sought after. Join us as we discuss: 13 May 2021